难治性心力衰竭药物治疗的研究进展  

A review of the studies on drug therapy for refractory heart failure

作　　者：成科 马丽(综述)[1] 毛庆菊(审校)[2] CHENG Ke;MA Li;MAO Qing-ju(Department of Cardiovascular Medicine,Tianyou Hospital Affiliated to Wuhan University of Science and Technology,Hubei 430064,China)

机构地区：[1]武汉科技大学附属天佑医院心血管内科,湖北430064 [2]武汉科技大学附属天佑医院中西医结合科,湖北430064

出　　处：《中国临床新医学》2023年第8期864-869,共6页CHINESE JOURNAL OF NEW CLINICAL MEDICINE

基　　金：湖北省教育厅科研计划项目(编号:B2019013)。

摘　　要：近年来,难治性心力衰竭(RHF)的发病率呈明显上升趋势。RHF患者存在严重的临床症状、较差的生活质量以及不良预后的问题。尽管现代医学的治疗手段不断丰富,但RHF的治疗仍是个难题。为更好地改善RHF患者预后,该文将对现有关于RHF药物治疗的研究进展作一综述。In recent years,the incidence of refractory heart failure(RHF)has increased significantly,and RHF patients have serious clinical symptoms,poorer quality of life and poor prognosis.Despite the continuous enrichment of modern medical treatment methods,the treatment of RHF has always been a challenge.In order to better improve the prognosis of RHF patients,this paper reviews the current studies on drug therapy for RHF.

关 键 词：难治性心力衰竭 神经体液系统抑制治疗 钠葡萄糖协同转运蛋白2抑制剂 利尿剂 正性肌力药物 

分 类 号：R541[医药卫生—心血管疾病]